12:42 PM EDT, 04/02/2024 (MT Newswires) -- Evaxion Biotech ( EVAX ) said Tuesday that three studies showed antigens from its preclinical EVX-B1 vaccine candidate significantly protected large, non-rodent animals against surgical site infections caused by Staphylococcus aureus.

The company said it is discussing options to move forward with an unnamed collaborator.

Evaxion shares jumped 17% in recent trading.

Price: 3.78, Change: +0.55, Percent Change: +17.03